FDA grants orphan status to two Lux products

The FDA has granted orphan drug designation to two of Lux Bioscience's investigational therapies.

Related Content:

ArticlesInflammation & Infection

IRISS registry study offers real-world outcomes

DMO study shows robust efficacy of intravitreal dexamethasone implant

The quest for topical treatments for the posterior segment